A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger …

AO Aliprantis, CA Shaw, P Griffin… - Human vaccines & …, 2021 - Taylor & Francis
ABSTRACT Respiratory Syncytial Virus (RSV) causes lower respiratory tract infections that
can be severe and sometimes fatal. The risk for severe RSV infection is highest in infants …

A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger …

AO Aliprantis, CA Shaw, P Griffin… - Human Vaccines & …, 2020 - europepmc.org
ABSTRACT Respiratory Syncytial Virus (RSV) causes lower respiratory tract infections that
can be severe and sometimes fatal. The risk for severe RSV infection is highest in infants …

[HTML][HTML] A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy …

AO Aliprantis, CA Shaw, P Griffin… - Human Vaccines & …, 2021 - ncbi.nlm.nih.gov
ABSTRACT Respiratory Syncytial Virus (RSV) causes lower respiratory tract infections that
can be severe and sometimes fatal. The risk for severe RSV infection is highest in infants …

[引用][C] A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy …

AO Aliprantis, CA Shaw, P Griffin… - Human Vaccines …, 2020 - espace.library.uq.edu.au
Respiratory Syncytial Virus (RSV) causes lower respiratory tract infections that can be
severe and sometimes fatal. The risk for severe RSV infection is highest in infants and older …

[引用][C] A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy …

AO Aliprantis, CA Shaw, P Griffin, N Farinola… - Human Vaccines & …, 2020 - cir.nii.ac.jp
A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of
an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults | CiNii …

A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger …

AO Aliprantis, CA Shaw, P Griffin… - Human vaccines & …, 2021 - pubmed.ncbi.nlm.nih.gov
Respiratory Syncytial Virus (RSV) causes lower respiratory tract infections that can be
severe and sometimes fatal. The risk for severe RSV infection is highest in infants and older …